[go: up one dir, main page]

SE0401345D0 - Therapeutic compounds: Pyridine as scaffold - Google Patents

Therapeutic compounds: Pyridine as scaffold

Info

Publication number
SE0401345D0
SE0401345D0 SE0401345A SE0401345A SE0401345D0 SE 0401345 D0 SE0401345 D0 SE 0401345D0 SE 0401345 A SE0401345 A SE 0401345A SE 0401345 A SE0401345 A SE 0401345A SE 0401345 D0 SE0401345 D0 SE 0401345D0
Authority
SE
Sweden
Prior art keywords
sup
scaffold
pyridine
therapeutic compounds
compounds
Prior art date
Application number
SE0401345A
Other languages
English (en)
Inventor
Ziping Liu
Claire Milburn
Maxime C Tremblay
Christopher Walpole
Zhongyong Wei
Hua Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32589804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0401345(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0401345A priority Critical patent/SE0401345D0/sv
Publication of SE0401345D0 publication Critical patent/SE0401345D0/sv
Priority to TW094115320A priority patent/TW200607799A/zh
Priority to CNA2005800246960A priority patent/CN101001840A/zh
Priority to PCT/SE2005/000753 priority patent/WO2005115986A1/en
Priority to EP05745177A priority patent/EP1756060A1/en
Priority to BRPI0511531-0A priority patent/BRPI0511531A/pt
Priority to KR1020067024936A priority patent/KR20070026540A/ko
Priority to US11/569,315 priority patent/US20070225292A1/en
Priority to RU2006145205/04A priority patent/RU2006145205A/ru
Priority to MXPA06013538A priority patent/MXPA06013538A/es
Priority to AU2005247834A priority patent/AU2005247834A1/en
Priority to CA002565065A priority patent/CA2565065A1/en
Priority to JP2007514980A priority patent/JP2008500336A/ja
Priority to ARP050102119A priority patent/AR049110A1/es
Priority to UY28923A priority patent/UY28923A1/es
Priority to IL179149A priority patent/IL179149A0/en
Priority to ZA200609765A priority patent/ZA200609765B/xx
Priority to NO20065878A priority patent/NO20065878L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0401345A 2004-05-25 2004-05-25 Therapeutic compounds: Pyridine as scaffold SE0401345D0 (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE0401345A SE0401345D0 (sv) 2004-05-25 2004-05-25 Therapeutic compounds: Pyridine as scaffold
TW094115320A TW200607799A (en) 2004-05-25 2005-05-12 Therapeutic compounds: pyridine as scaffold
CA002565065A CA2565065A1 (en) 2004-05-25 2005-05-20 Therapeutic compounds: pyridine as scaffold
JP2007514980A JP2008500336A (ja) 2004-05-25 2005-05-20 治療化合物：骨格としてのピリジン
US11/569,315 US20070225292A1 (en) 2004-05-25 2005-05-20 Therapeutic Compounds: Pyridine as Scaffold
MXPA06013538A MXPA06013538A (es) 2004-05-25 2005-05-20 Compuestos terapeuticos: piridina como soporte.
EP05745177A EP1756060A1 (en) 2004-05-25 2005-05-20 Therapeutic compounds: pyridine as scaffold
BRPI0511531-0A BRPI0511531A (pt) 2004-05-25 2005-05-20 composto, uso de um composto, composição farmacêutica, e, métodos para terapia de distúrbios gastrointestinais funcionais, de sìndrome do intestino irritável e de distúrbio de refluxo gastro-esofágico e para preparar um composto
KR1020067024936A KR20070026540A (ko) 2004-05-25 2005-05-20 치료 화합물：스캐폴드로서의 피리딘
CNA2005800246960A CN101001840A (zh) 2004-05-25 2005-05-20 治疗用化合物：作为骨架的吡啶
RU2006145205/04A RU2006145205A (ru) 2004-05-25 2005-05-20 Терапевтические соединения: пиридин в качестве каркаса
PCT/SE2005/000753 WO2005115986A1 (en) 2004-05-25 2005-05-20 Therapeutic compounds: pyridine as scaffold
AU2005247834A AU2005247834A1 (en) 2004-05-25 2005-05-20 Therapeutic compounds: Pyridine as scaffold
ARP050102119A AR049110A1 (es) 2004-05-25 2005-05-23 Compuestos terapeuticos: piridina como andamiaje estructural
UY28923A UY28923A1 (es) 2004-05-25 2005-05-25 Compuestos terapéuticos: piridina como estructura base
IL179149A IL179149A0 (en) 2004-05-25 2006-11-09 Therapeutic compounds: pyridine as scaffold
ZA200609765A ZA200609765B (en) 2004-05-25 2006-11-23 Therapeutic compounds: pyridine as scaffoid
NO20065878A NO20065878L (no) 2004-05-25 2006-12-18 Terapeutiske forbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401345A SE0401345D0 (sv) 2004-05-25 2004-05-25 Therapeutic compounds: Pyridine as scaffold

Publications (1)

Publication Number Publication Date
SE0401345D0 true SE0401345D0 (sv) 2004-05-25

Family

ID=32589804

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401345A SE0401345D0 (sv) 2004-05-25 2004-05-25 Therapeutic compounds: Pyridine as scaffold

Country Status (18)

Country Link
US (1) US20070225292A1 (sv)
EP (1) EP1756060A1 (sv)
JP (1) JP2008500336A (sv)
KR (1) KR20070026540A (sv)
CN (1) CN101001840A (sv)
AR (1) AR049110A1 (sv)
AU (1) AU2005247834A1 (sv)
BR (1) BRPI0511531A (sv)
CA (1) CA2565065A1 (sv)
IL (1) IL179149A0 (sv)
MX (1) MXPA06013538A (sv)
NO (1) NO20065878L (sv)
RU (1) RU2006145205A (sv)
SE (1) SE0401345D0 (sv)
TW (1) TW200607799A (sv)
UY (1) UY28923A1 (sv)
WO (1) WO2005115986A1 (sv)
ZA (1) ZA200609765B (sv)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
US8536182B2 (en) 2005-07-26 2013-09-17 Glaxo Group Limited Benzylpiperazine derivatives and their medical use
AR057987A1 (es) * 2005-11-24 2008-01-09 Astrazeneca Ab Compuestos agonistas de cb1 (receptor cannabinoide)
GB0524814D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
JP5306986B2 (ja) 2006-03-16 2013-10-02 エボテック （ユーエス） インコーポレイテッド Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
WO2007140439A2 (en) 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
DK2041093T3 (da) 2006-06-28 2010-08-02 Glaxo Group Ltd Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
EP2142522A1 (en) 2007-03-28 2010-01-13 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
MX2009012374A (es) 2007-05-18 2009-12-01 Abbott Lab Compuestos novedosos como ligandos del receptor de canabinoides.
US8338623B2 (en) * 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
EP2070924A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel
EP2070916A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
KR101257158B1 (ko) 2008-05-23 2013-04-23 노파르티스 아게 단백질 티로신 키나제 억제제로서의 퀴놀린 및 퀴녹살린의 유도체
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8859596B2 (en) 2008-09-16 2014-10-14 Abbvie Inc. Compounds as cannabinoid receptor ligands
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
HRP20160967T1 (hr) * 2009-10-06 2016-10-07 Millennium Pharmaceuticals, Inc. Heterociklički spojevi korisni kao pdk1 inhibitori
WO2014013951A1 (ja) 2012-07-19 2014-01-23 日本曹達株式会社 ピリジン化合物および農園芸用殺菌剤
KR20140011780A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
JP2016535755A (ja) 2013-11-06 2016-11-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｇｓｋ−３阻害剤
MX2016005759A (es) 2013-11-06 2016-07-18 Squibb Bristol Myers Co Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
JP2019131470A (ja) * 2016-05-20 2019-08-08 石原産業株式会社 Ｎ−（４−ピリジル）ベンズアミド化合物又はその塩を有効成分として含有する有害生物防除剤
AR111422A1 (es) 2017-04-27 2019-07-10 Ishihara Sangyo Kaisha Compuestos de n-(4-piridil)nicotinamida o sal del mismo
CN107880024A (zh) * 2017-12-11 2018-04-06 张玉玲 一种用于治疗炎症的大麻素受体激动剂及其合成方法
EP4065546A1 (en) * 2019-11-25 2022-10-05 Gain Therapeutics SA Aryl and heteroaryl compounds, and therapeutic uses thereof in conditions associated with the alteration of the activity of galactocerebrosidase
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046871A1 (de) * 1980-12-12 1982-07-22 Dr. Karl Thomae Gmbh, 7950 Biberach Neue chinazolinone, ihre herstellung und ihre verwendung als arzneimittel
DE3166627D1 (en) * 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
ZA200305582B (en) * 2001-03-05 2004-07-19 Du Pont Heterocyclic diamide invertebrate pest control agents.
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CN101001840A (zh) 2007-07-18
RU2006145205A (ru) 2008-06-27
EP1756060A1 (en) 2007-02-28
TW200607799A (en) 2006-03-01
CA2565065A1 (en) 2005-12-08
IL179149A0 (en) 2007-03-08
WO2005115986A1 (en) 2005-12-08
MXPA06013538A (es) 2007-01-26
AU2005247834A1 (en) 2005-12-08
US20070225292A1 (en) 2007-09-27
KR20070026540A (ko) 2007-03-08
JP2008500336A (ja) 2008-01-10
ZA200609765B (en) 2008-08-27
AR049110A1 (es) 2006-06-28
NO20065878L (no) 2007-02-21
UY28923A1 (es) 2005-12-30
BRPI0511531A (pt) 2008-01-02

Similar Documents

Publication Publication Date Title
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
SE0401342D0 (sv) Therapeutic compounds
SE0401971D0 (sv) Piperidne derivatives
SE0402762D0 (sv) Indazole sulphonamide derivatives
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
TW200716628A (en) Novel compounds
SE9900961D0 (sv) Novel compounds
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0203300D0 (sv) Novel Compounds
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0300105D0 (sv) Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0302571D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
SE0400027D0 (sv) Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
SE0401343D0 (sv) Therapeutic compounds: Pyridine N oxide as scaffold
SE0301445D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0402763D0 (sv) Nitro indazole derivatives
SE0300103D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
SE0400285D0 (sv) Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
SE0300104D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof